Related Experiment Video

Updated: Aug 30, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

T-Box Transcription Factor 2 Enhances Chemoresistance of Endometrial Cancer by Mediating NRF2 Expression

Ning Ding1, Ting Zhang1, Xiaohui Yu1

  • 1Department of Gynaecology, Zibo Central Hospital, No. 54 Gongqingtuan Road, Zhangdian District, Zibo 255036, Shandong, China.

Current Protein & Peptide Science
|August 26, 2022
PubMed
Abstract

Insights

T-Box transcription factor 2 (TBX2) enhances cisplatin resistance in endometrial cancer. This occurs by regulating the nuclear factor erythroid 2-related factor 2 (NRF2) signaling pathway, impacting cell viability and tumor growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The role of T-Box transcription factor 2 (TBX2) in endometrial cancer remains unclear.
  • Investigating TBX2's function and mechanisms in endometrial cancer is crucial for understanding treatment resistance.

Purpose of the Study:

  • To explore the role of TBX2 in endometrial cancer.
  • To elucidate the underlying mechanisms by which TBX2 influences endometrial cancer progression and chemoresistance.

Main Methods:

  • TBX2 expression was manipulated (knockdown/overexpression) in endometrial cancer cell lines using lentivirus transduction.
  • Cell viability was assessed via CCK-8 assay; gene and protein levels were analyzed by qPCR and Western blotting.
  • Interactions between TBX2 and nuclear factor erythroid 2-related factor 2 (NRF2) were investigated using ChIP assays and xenograft models.

Main Results:

  • TBX2 was found to be upregulated in cisplatin-resistant endometrial cancer tissues and cells.
  • TBX2 significantly regulated cell viability and cisplatin resistance in endometrial cancer.
  • TBX2's effects on chemoresistance were linked to the NRF2 signaling pathway, confirmed in both cell lines and a xenograft model.

Conclusions:

  • TBX2 plays a key role in enhancing cisplatin resistance in endometrial cancer.
  • The mechanism involves the regulation of the NRF2 signaling pathway by TBX2.
  • Targeting TBX2 or the NRF2 pathway may offer therapeutic strategies for overcoming chemoresistance in endometrial cancer.
Keywords:
Endometrial cancerNRF2TBX2chemo-resistancecisplatin resistancemRNA

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.5K

Related Concept Videos

Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K